CSU Drug Pipeline: Anti-IgE & Mast Cell Targets — PatSnap Eureka
Chronic Spontaneous Urticaria: Anti-IgE, Anti-Siglec-8 & Next-Gen Mast Cell Therapies
From omalizumab to barzolvolimab and lirentelimab — the CSU pipeline is bifurcating toward mast cell depletion and precision biomarker-guided strategies. Explore patent signals from Allakos, Celldex, Regeneron, and Roche in one intelligence layer.
What Drives CSU — and Why Current Therapy Falls Short
Chronic spontaneous urticaria (CSU) is characterised by recurring wheals, angioedema, and pruritus driven by dysregulated mast cell and basophil activation. Multiple patent filings explicitly articulate the mechanistic cascade: FcεRI activation — via agonistic autoantibodies or antigen cross-linking of surface-bound IgE — triggers degranulation and release of histamine and pro-inflammatory mediators, driving tissue edema and pruritus. According to retrieved Regeneron Pharmaceuticals filings, both IgE-dependent and autoantibody-mediated pathways converge on mast cells and basophils as the proximate effectors of CSU symptoms.
Omalizumab (XOLAIR®) is the approved anti-IgE benchmark for H1-antihistamine-refractory CSU. However, Allakos filings cite omalizumab response rates of only 55–80% in refractory patients — establishing the clinical rationale for all next-generation approaches including anti-Siglec-8, anti-KIT, IL-4Rα, and BTK inhibition. The field is now rapidly evolving beyond first-generation anti-IgE therapy toward novel biologics, reflecting unmet need in patients refractory to current standards, as tracked by the World Health Organization in its global allergy burden reporting.
Biomarker-guided patient stratification is emerging as a critical layer: the Genentech/Roche tryptase biomarker framework distinguishes Th2-high versus tryptase-high patient subgroups, while the University of Washington patent identifies microRNAs as predictive biomarkers for anti-IgE therapeutic response. Companion diagnostic co-development may be required to maximise the commercial potential of mast cell-directed therapies.
Filing Activity by Target & Assignee
Quantitative patent signals from the CSU innovation landscape, 2019–2025, derived from PatSnap Eureka analysis.
CSU Patent Filings by Molecular Target (2019–2025)
IL-4Rα leads by filing count (9+, Regeneron/Sanofi), followed by Siglec-8 (7+, Allakos) — the two most aggressively prosecuted new target classes in CSU.
Omalizumab Response Rate in Refractory CSU Patients
Allakos filings cite 55–80% response rates for omalizumab in refractory CSU, leaving 20–45% of patients with inadequate control — the unmet need driving the entire next-generation pipeline.
CSU Pipeline: Agents, Targets & Development Stage
Seven distinct therapeutic modalities are represented in patent filings and literature from 2019–2025, spanning approved agents to early-stage biomarker-guided approaches.
| Agent / Class | Target | Assignee | Modality | Stage | Key CSU Positioning |
|---|---|---|---|---|---|
| Omalizumab (XOLAIR®) | IgE / FcεRI | Novartis AG | Anti-IgE mAb | Approved | H1-antihistamine-refractory CSU; benchmark for next-gen agents |
| Ligelizumab | IgE / FcεRI | Novartis AG | Anti-IgE mAb (next-gen) | Phase 3 | Phase 2 and Phase 3 data referenced; H1-AH-refractory CSU |
| Lirentelimab (AK002) | Siglec-8 | Allakos Inc. | Anti-Siglec-8 mAb | Clinical | Refractory to H1-antihistamines and/or anti-IgE; dual mast cell/eosinophil mechanism |
| Barzolvolimab | KIT (c-Kit / CD117) | Celldex Therapeutics | Anti-KIT mAb | Phase 2/3 | Post-omalizumab, post-dupilumab, post-ligelizumab salvage positioning |
| Dupilumab | IL-4Rα | Regeneron / Sanofi | Anti-IL-4Rα mAb | Clinical | IL-4/IL-13 dual blockade; covers CSU and chronic inducible urticaria |
Map the Full CSU Competitive Landscape
Compare claim scope, assignee strategy, and jurisdictional coverage for every CSU target in PatSnap Eureka.
Principal Molecular Targets & Patent Findings
Each target class carries distinct mechanistic rationale, assignee concentration, and clinical positioning signals from the 2019–2025 patent dataset.
IgE / FcεRI — Omalizumab & Ligelizumab
The most established axis in this dataset. Omalizumab is the approved anti-IgE benchmark; ligelizumab (Novartis) is described as a next-generation IgE antagonist with completed Phase 2 and Phase 3 data referenced. Novartis further describes Treg cell dysfunction as a non-canonical rationale for anti-IgE therapy extending beyond simple IgE neutralization. The life sciences patent intelligence platform tracks both agents across global jurisdictions. According to the European Academy of Allergy and Clinical Immunology, CSU management guidelines continue to evolve around this axis.
Response rate: 55–80% in refractory patientsSiglec-8 — Lirentelimab (AK002) by Allakos
The most heavily patented new target in this dataset for CSU specifically. At least 7 Allakos filings across WO, US, CA, AU, IL, BR, JP, and ID claim anti-Siglec-8 antibody methods for chronic urticaria. Siglec-8 engagement on mast cells suppresses their activation; on eosinophils it induces apoptosis. Allakos filings note that eosinophils enhance mast cell activity through the extrinsic coagulation cascade in CSU lesions, establishing a dual eosinophil/mast cell rationale. Positioned for patients refractory to H1-antihistamines and/or anti-IgE therapy.
7+ jurisdictions · Focused single-asset global IPKIT (c-Kit / CD117) — Barzolvolimab by Celldex
KIT is a receptor tyrosine kinase indispensable for mast cell survival, homeostasis, and proliferation. The Celldex barzolvolimab WO filing (2025) explicitly positions KIT antagonism for patients who have failed omalizumab, ligelizumab, dupilumab, and anti-IL-5R agents — language consistent with Phase 2/3 trial enrollment criteria. The Celldex CN filing simultaneously covers chronic inducible urticaria, mastocytosis, mast cell activation syndrome (MCAS), and over 30 other mast cell-associated disorders under the same anti-KIT therapeutic umbrella. A Celldex BR filing title explicitly includes "conjugate," suggesting ADC formats are being considered.
Post-omalizumab, post-dupilumab salvage positioningIL-4Rα — Dupilumab by Regeneron / Sanofi
Regeneron holds at least 9 filings across WO, US, CA, AU, JP, IL, BR, MX, and NZ for dupilumab in CSU — the most prolific assignee by filing count in this dataset. IL-4 stimulates mast cell proliferation and promotes IgE class switching; IL-4/IL-13 dual blockade via IL-4Rα antagonism is expected to reduce the inflammatory substrate underlying urticaria. A separate Sanofi CN filing also covers chronic inducible cold urticaria (ColdU). Regeneron filings also describe combination of anti-IL-4Rα with anti-BCMA/anti-CD3 bispecific antibodies to ablate IgE+ plasma cells — a potentially disease-modifying approach tracked by PatSnap analytics.
9+ jurisdictions · Highest commercial prosecution priorityNext-Generation Combination Approaches in CSU
Retrieved patent filings signal several combination and next-generation strategies extending beyond single-agent biologics.
IL-4/IL-13 Inhibitor + Plasma Cell Ablation
Regeneron filings (CN 2021, 2025; BR 2024) explicitly describe combination of anti-IL-4Rα antibody (dupilumab) with anti-BCMA/anti-CD3 bispecific antibodies to ablate IgE+ plasma cells while blocking new IgE+ plasma cell generation — a mechanistically comprehensive approach to eliminating allergen-specific IgE. This represents a potentially disease-modifying strategy, not merely symptomatic control.
Biomarker-Guided Mast Cell Targeting
The Genentech/Roche tryptase biomarker framework signals a move toward precision patient selection — directing tryptase-high patients to mast cell-directed monotherapy versus those with elevated Th2 biomarkers toward combination with Th2 pathway inhibitors. The University of Washington patent identifies microRNAs as predictive biomarkers for anti-IgE therapeutic response, signalling that companion diagnostic co-development may be required.
BTK Inhibitor + JAK Inhibitor
The Roche fenebrutinib filing references combination with JAK inhibitors (tofacitinib, baricitinib, filgotinib, peficitinib, upadacitinib) as a potential approach in the context of diseases covered, which include CSU. BTK lies downstream of FcεRI and B-cell receptor signaling; BTK inhibition is mechanistically expected to suppress both mast cell activation and autoantibody production in autoimmune-driven CSU.
IL-4R Antagonist + Allergen-Specific Immunotherapy
Regeneron filings describe combinations of dupilumab with allergen-specific immunotherapy (SIT) to enhance safety and efficacy — a strategy with potential applicability to CSU patients with defined allergic triggers. This reflects a broader multi-indication strategy for dupilumab across Th2-mediated conditions including atopic dermatitis, asthma, prurigo nodularis, and urticaria subtypes.
Who Is Filing — and What It Signals
Activity in this dataset is overwhelmingly patent-driven. Among retrieved results, the following organisations are most active in CSU-specific patent filings. Allakos Inc. holds the most concentrated single-target patent cluster in the dataset — at least 7 filings across WO, US, CA, AU, IL, BR, JP, and ID, all covering anti-Siglec-8 antibody methods for chronic urticaria. This represents a focused, single-asset global IP strategy.
Regeneron Pharmaceuticals, Inc. is the most prolific assignee by filing count, with at least 9 filings across WO, US, CA, AU, JP, IL, BR, MX, and NZ, all covering dupilumab for CSU. The scale of multi-jurisdictional prosecution signals high commercial priority. Celldex Therapeutics holds two CSU-relevant KIT-targeting filings (WO dosing/methods for barzolvolimab; BR antibody composition), with the 2025 WO filing language consistent with Phase 2/3 trial enrollment criteria. Academic patent signals come from the University of Washington (miRNA biomarkers) and Bnai Zion Medical Center (anti-IL-17). Researchers can explore the full assignee landscape through PatSnap's IP analytics platform, which integrates with databases from the World Intellectual Property Organization and the European Patent Office.
The anti-KIT antibody class (barzolvolimab) positions itself explicitly as a post-omalizumab, post-dupilumab, post-Siglec-8 salvage therapy — suggesting a late-line market segment. The breadth of Celldex KIT patent claims (covering CSU, inducible urticaria, MCAS, mastocytosis) creates potential for a mast cell disease franchise, but also increases freedom-to-operate complexity.
Chronic Spontaneous Urticaria Drug Pipeline — key questions answered
Omalizumab (XOLAIR®) is described as an approved anti-IgE antibody for H1-antihistamine-refractory CSU. It is the established benchmark against which next-generation agents such as ligelizumab and anti-Siglec-8 antibodies are positioned.
Lirentelimab (AK002) is an anti-Siglec-8 antibody developed by Allakos Inc. Siglec-8 is an inhibitory receptor whose engagement on mast cells suppresses their activation and on eosinophils induces apoptosis, providing a dual mast cell/eosinophil rationale. Retrieved Allakos filings position anti-Siglec-8 therapy for patients refractory or insufficiently responsive to H1-antihistamines and/or anti-IgE therapy.
Barzolvolimab is an anti-KIT (c-Kit / CD117) antibody developed by Celldex Therapeutics. KIT is a receptor tyrosine kinase expressed on mast cell surfaces that is indispensable for mast cell survival, homeostasis, and proliferation. The Celldex filings specifically describe its use in chronic urticaria patients who have failed omalizumab, ligelizumab, dupilumab, or other biologics.
Retrieved filings from Regeneron Pharmaceuticals and Sanofi describe that IL-4 stimulates mast cell proliferation and promotes the Th2 cytokine milieu including IgE production. IL-4/IL-13 dual blockade via IL-4Rα antagonism (dupilumab) is expected to reduce the inflammatory substrate underlying urticaria. A separate Sanofi filing also covers chronic inducible cold urticaria as an indication.
The Genentech/Roche tryptase biomarker filings describe patient selection methodologies using tryptase allele count or tryptase expression levels, distinguishing Th2-high versus tryptase-high patient subgroups to direct appropriate therapy. The University of Washington patent identifies microRNAs as predictive biomarkers for anti-IgE therapeutic response.
Allakos Inc. holds at least 7 filings across WO, US, CA, AU, IL, BR, JP, and ID jurisdictions for anti-Siglec-8 antibody methods. Regeneron Pharmaceuticals holds at least 9 filings across WO, US, CA, AU, JP, IL, BR, MX, and NZ for dupilumab (anti-IL-4R) in CSU. Celldex Therapeutics, Novartis AG, and Hoffmann-La Roche/Genentech are also active assignees.
Still have questions about the CSU pipeline? Let PatSnap Eureka search the patent literature for you.
Ask PatSnap Eureka a CSU QuestionAccelerate Your CSU Drug Discovery & Competitive Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from target identification to freedom-to-operate analysis across the full CSU pipeline.
References
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2019, WO [Patent]
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2019, CA [Patent]
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2021, US [Patent]
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2020, AU [Patent]
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2020, IL [Patent]
- Methods and Compositions for the Treatment of Chronic Urticaria — Allakos Inc., 2021, BR [Patent]
- Methods and compositions for treating chronic urticaria — Allakos Inc., 2021, JP [Patent]
- Methods and compositions for treating chronic urticaria (CN) — Allakos Inc., 2021, CN [Patent]
- Methods and Compositions for Treatment of Chronic Urticaria — Allakos Inc., 2021, ID [Patent]
- MicroRNAs as predictors of response to anti-IgE therapies in chronic spontaneous urticaria — University of Washington, 2021, WO [Patent]
- Methods of treating chronic spontaneous urticaria with ligelizumab — Novartis AG, 2021, CN [Patent]
- Treatment methods using omalizumab — Novartis AG, 2022, CN [Patent]
- Methods for treating chronic spontaneous urticaria by administering an IL-4R antagonist — Regeneron Pharmaceuticals, 2023, WO [Patent]
- Methods for treating chronic spontaneous urticaria by administering an IL-4R antagonist — Regeneron Pharmaceuticals, 2023, US [Patent]
- Methods for treating chronic spontaneous urticaria by administering an IL-4R antagonist — Regeneron Pharmaceuticals, 2024, BR [Patent]
- Anti-kit antibody dosing and methods — Celldex Therapeutics, 2025, WO [Patent]
- Anti-KIT antibody and uses thereof — Celldex Therapeutics, 2023, CN [Patent]
- Treatment of mast cell-related disorders — Novel Nobles (Novelty Nobility), 2024, CN [Patent]
- Methods for treating RA, CSU, and SLE using BTK inhibitors (fenebrutinib) — Hoffmann-La Roche AG, 2021, CN [Patent]
- Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases — Hoffmann-La Roche AG, 2020, CN [Patent]
- Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases — Genentech, Inc., 2021, JP [Patent]
- Anti-IL-17 antibody for use in treating chronic spontaneous urticaria — Bnai Zion Medical Center, 2020, WO [Patent]
- World Intellectual Property Organization (WIPO) — Global patent database
- European Patent Office (EPO) — Patent search and analysis
- European Academy of Allergy and Clinical Immunology (EAACI) — CSU management guidelines
- World Health Organization (WHO) — Global allergy burden reporting
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals only — it should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.